Bayer consensus sees earnings rebound. Bayer stock sits 19.40 percent below its high

Published on 10/20/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock costs EUR 43.46 on October 20, 2026, 0.14 percent above the Xetra close. The October 19 consensus expects EUR 0.387 earnings per share.

Earnings expectations set the test

On October 19, 2026, consensus expected EUR 0.387 earnings per share for Bayer's third quarter.
Bayer's second-quarter 2026 sales reached EUR 10.872 billion after a 2.20 percent increase.
Bayer stock trades at EUR 43.46 at 10:12 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.14 percent above the Xetra close of October 19, 2026.
Bayer will publish third-quarter results on November 3, 2026.

Aquarellbild einer Industriestadt-Skyline am Flussufer mit sanften Farbverläufen — Bayer AG (DE000BAY0017): Aquarellmalerei der Skyline von Leverkusen mit Industrieanlagen am Rhein, Illustration mit AI erstellt.

Bayer stock (ISIN DE000BAY0017) was trading at EUR 43.46 at Lang & Schwarz on October 20, 2026, at 10:12 a.m. CEST, 0.14 percent above the Xetra close of October 19, 2026. A consensus published by Stock World on October 19, 2026, expected Bayer to return to positive earnings per share in the third quarter.

Consensus favors earnings recovery

The estimate put third-quarter earnings per share at EUR 0.387, compared with a loss of EUR 0.980 in the prior-year quarter. Expected revenue of EUR 9.87 billion represented a 2.19 percent increase from the prior-year period, making the earnings comparison more important than sales growth for the November report.

The same consensus expected full-year earnings per share of EUR 4.52, versus a loss of EUR 3.680 in the prior year. Full-year revenue was projected at EUR 45.80 billion, compared with EUR 45.58 billion previously. These are estimates, not reported results.

What does the analyst view imply?

JPMorgan kept an Overweight rating and a EUR 61.00 target in a research note dated October 16, 2026, according to MarketScreener. UBS also retained its Buy rating and EUR 62.00 target in a note dated October 15, 2026, the same outlet reported. Against the October 20 Lang & Schwarz price, those targets stand 40.31 percent and 42.77 percent above the price, respectively.

Three events shape the timeline

On September 17, 2026, Bayer said the FDA approved finerenone for chronic kidney disease associated with type 1 diabetes, describing it as the first approved treatment option in more than 30 years. On October 2, 2026, the company announced a USD 2.20 billion investment in a US manufacturing site. On October 19, 2026, the consensus projected EUR 0.387 earnings per share for the third quarter. The company announcements appear on Bayer, while the latest estimate came from Stock World.

November 3 brings two dates

On November 3, 2026, Bayer will publish its third-quarter results at 7:30 a.m. CET and hold the related investor video call at 2:00 p.m. CET, according to the company's Bayer event page. The report will test whether the expected earnings recovery is supported by operating performance.

Stock remains below its yearly high

Bayer stock is 19.40 percent below its 52-week high of EUR 53.92 and above its 52-week low of EUR 25.78. The market capitalization stood at EUR 42.6 billion as of October 20, 2026, while the latest second-quarter report showed sales of EUR 10.872 billion, up 2.20 percent on a currency- and portfolio-adjusted basis. The stock was trading at EUR 43.46 at Lang & Schwarz on October 20, 2026, at 10:12 a.m. CEST, 0.14 percent above the Xetra close of October 19, 2026. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.